Simply Wall St.2d agoneutral
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They AppearAbbVie Inc.'s ( NYSE:ABBV ) stock was strong despite it releasing a soft earnings report last week. Our analysis...
Notícias
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
53last 24h
1680last 7d
314🟢 bullish (7d)
170🔴 bearish (7d)
136publishers
Simply Wall St.4d agobullish
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings OutlookAbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
